Concert Pharmaceuticals Inc. (CNCE)

10.93
0.20 1.86
NASDAQ : Health Technology
Prev Close 10.73
Open 10.69
Day Low/High 10.69 / 11.13
52 Wk Low/High 9.21 / 17.83
Volume 141.41K
Avg Volume 169.30K
Exchange NASDAQ
Shares Outstanding 23.80M
Market Cap 249.42M
EPS -2.40
P/E Ratio N/A
Div & Yield N.A. (N.A)
Concert Pharmaceuticals Completes Enrollment Of 12 Mg Cohort In Phase 2a Trial Of CTP-543 In Alopecia Areata

Concert Pharmaceuticals Completes Enrollment Of 12 Mg Cohort In Phase 2a Trial Of CTP-543 In Alopecia Areata

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed patient enrollment of the final cohort evaluating 12 mg twice daily of CTP-543 in its Phase 2a trial for the treatment of moderate-to-severe alopecia areata.

Noteworthy Friday Option Activity: CNCE, UIHC, RDFN

Noteworthy Friday Option Activity: CNCE, UIHC, RDFN

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Concert Pharmaceuticals Inc , where a total of 2,013 contracts have traded so far, representing approximately 201,300 underlying shares. That amounts to about 146.5% of CNCE's average daily trading volume over the past month of 137,375 shares.

CNCE: Insiders Vs. Shorts

CNCE: Insiders Vs. Shorts

The most recent short interest data was recently released for the 12/14/2018 settlement date, and Concert Pharmaceuticals Inc is one of the most shorted stocks of the Russell 3000, based on 4.94 "days to cover" versus the median component at 4.32. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Concert Pharmaceuticals Initiates Phase 1 Clinical Program Of CTP-692 For The Treatment Of Schizophrenia

Concert Pharmaceuticals Initiates Phase 1 Clinical Program Of CTP-692 For The Treatment Of Schizophrenia

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated its Phase 1 clinical program for CTP-692, which is being developed as a novel adjunctive treatment for schizophrenia, a devastating, chronic illness with significant unmet...

Oversold Conditions For Concert Pharmaceuticals (CNCE)

Oversold Conditions For Concert Pharmaceuticals (CNCE)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Concert Pharmaceuticals Reports Positive CTP-543 Results From Interim Analysis Of Phase 2a Trial In Patients With Alopecia Areata

Concert Pharmaceuticals Reports Positive CTP-543 Results From Interim Analysis Of Phase 2a Trial In Patients With Alopecia Areata

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced interim topline results from the first two cohorts of its Phase 2a trial evaluating its investigational treatment CTP-543 in patients with moderate-to-severe alopecia areata, an autoimmune...

Concert Pharmaceuticals To Participate At Upcoming Investor Conferences

Concert Pharmaceuticals To Participate At Upcoming Investor Conferences

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate at the following upcoming investor conferences: The Stifel 2018 Healthcare Conference on November 14, 2018, at 2:00 p.

Concert Pharmaceuticals Presents Preclinical Data On CTP-692, A Novel Drug Candidate For Schizophrenia, Supporting Potential To Improve Safety Profile Of D-Serine

Concert Pharmaceuticals Presents Preclinical Data On CTP-692, A Novel Drug Candidate For Schizophrenia, Supporting Potential To Improve Safety Profile Of D-Serine

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today presented preclinical results that support the potential of CTP-692, the Company's novel drug candidate for schizophrenia, to improve the safety profile of D-serine.

Concert Pharmaceuticals Reports Third Quarter 2018 Financial Results And Provides Company Update

Concert Pharmaceuticals Reports Third Quarter 2018 Financial Results And Provides Company Update

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the third quarter of 2018.

Concert Pharmaceuticals To Report Third Quarter 2018 Financial Results On November 1, 2018

Concert Pharmaceuticals To Report Third Quarter 2018 Financial Results On November 1, 2018

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its third quarter 2018 financial results on Thursday, November 1, 2018, before the U.

Concert Pharmaceuticals Amends Protocol Of Phase 2a Trial To Evaluate 12 Mg Twice-Daily Dose Cohort Of CTP-543 For The Treatment Of Alopecia Areata

Concert Pharmaceuticals Amends Protocol Of Phase 2a Trial To Evaluate 12 Mg Twice-Daily Dose Cohort Of CTP-543 For The Treatment Of Alopecia Areata

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will include an additional cohort of patients in the Phase 2a trial evaluating CTP-543.

Concert Pharmaceuticals Enters Oversold Territory (CNCE)

Concert Pharmaceuticals Enters Oversold Territory (CNCE)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Concert Pharmaceuticals To Present At Upcoming Investor Conferences

Concert Pharmaceuticals To Present At Upcoming Investor Conferences

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the following upcoming investor conferences: The Wells Fargo Securities 2018 Healthcare Conference on September 5, 2018 at 10:15 a.

Concert Pharmaceuticals Reports Second Quarter 2018 Financial Results And Provides Company Update

Concert Pharmaceuticals Reports Second Quarter 2018 Financial Results And Provides Company Update

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the second quarter of 2018.

Concert Pharmaceuticals Is Now Oversold (CNCE)

Concert Pharmaceuticals Is Now Oversold (CNCE)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Concert Pharmaceuticals To Report Second Quarter 2018 Financial Results On August 2, 2018

Concert Pharmaceuticals To Report Second Quarter 2018 Financial Results On August 2, 2018

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its second quarter 2018 financial results on Thursday, August 2, 2018, before the U.

Relative Strength Alert For Concert Pharmaceuticals

Relative Strength Alert For Concert Pharmaceuticals

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Concert Pharmaceuticals Reports First Quarter 2018 Financial Results

Concert Pharmaceuticals Reports First Quarter 2018 Financial Results

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the first quarter of 2018.

Concert Pharmaceuticals To Report First Quarter 2018 Financial Results On May 3, 2018, And Present At Upcoming Investor Conferences

Concert Pharmaceuticals To Report First Quarter 2018 Financial Results On May 3, 2018, And Present At Upcoming Investor Conferences

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its first quarter 2018 financial results on Thursday, May 3, 2018, before the U.

Concert Pharmaceuticals Completes Enrollment In Phase 2a Trial Of CTP-543 In Alopecia Areata

Concert Pharmaceuticals Completes Enrollment In Phase 2a Trial Of CTP-543 In Alopecia Areata

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed patient enrollment of its Phase 2a trial evaluating CTP-543 for the treatment of moderate-to-severe alopecia areata.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: PNNT, PTN, VTSI Downgrades: BRN, CNCE, CRWS, DFIN, FF, HDSN, NRT, PFLT, WPM Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Concert Pharmaceuticals Present At Upcoming Investor Conferences

Concert Pharmaceuticals Present At Upcoming Investor Conferences

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the following upcoming investor conferences: The Cowen 38th Annual Healthcare Conference on...

First Week of CNCE March 16th Options Trading

First Week of CNCE March 16th Options Trading

Investors in Concert Pharmaceuticals Inc saw new options begin trading this week, for the March 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CNCE options chain for the new March 16th contracts and identified one put and one call contract of particular interest.

Concert Pharmaceuticals Reports Year Ended 2017 Financial Results

Concert Pharmaceuticals Reports Year Ended 2017 Financial Results

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today reported financial results for the year ended December 31, 2017, as well as provided an update on its product pipeline and corporate activities.

Concert Pharmaceuticals Announces Advancement Of Novel Drug Candidate In Schizophrenia

Concert Pharmaceuticals Announces Advancement Of Novel Drug Candidate In Schizophrenia

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the next development candidate in its product pipeline with the selection of CTP-692, a novel drug for adjunctive treatment of schizophrenia, a...

Concert Pharmaceuticals To Report Full Year 2017 Results On March 1, 2018

Concert Pharmaceuticals To Report Full Year 2017 Results On March 1, 2018

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the year ended December 31, 2017, on Thursday, March 1, 2018, before the U.

Concert Pharmaceuticals Announces Initiation Of Enrollment In Second Cohort Of CTP-543 Phase 2a Trial For Alopecia Areata

Concert Pharmaceuticals Announces Initiation Of Enrollment In Second Cohort Of CTP-543 Phase 2a Trial For Alopecia Areata

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated enrollment of the second cohort of its Phase 2a clinical trial evaluating CTP-543.

Commit To Purchase Concert Pharmaceuticals At $17.50, Earn 23.6% Annualized Using Options

Commit To Purchase Concert Pharmaceuticals At $17.50, Earn 23.6% Annualized Using Options

Investors eyeing a purchase of Concert Pharmaceuticals Inc stock, but cautious about paying the going market price of $19.90/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the July put at the $17.50 strike, which has a bid at the time of this writing of $1.90.

FDA Grants Fast Track Designation To Concert Pharmaceuticals' CTP-543 For The Treatment Of Alopecia Areata

FDA Grants Fast Track Designation To Concert Pharmaceuticals' CTP-543 For The Treatment Of Alopecia Areata

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the U.

Concert Pharmaceuticals Announces Patent Trial And Appeal Board Did Not Institute PGR Proceeding

Concert Pharmaceuticals Announces Patent Trial And Appeal Board Did Not Institute PGR Proceeding

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the Patent Trial and Appeal Board (PTAB) of the U.

TheStreet Quant Rating: D (Sell)